Talha Badar, Associate Professor of Medicine at Mayo Clinic, shared on X:
“Exciting to see the DELPHINUS results showing daratumumab with chemotherapy achieved an 83% overall response rate, enabled 75% of children with R/R T-ALL to proceed to allo-HSCT, and resulted in 24-month OS of 41%.
As co-chair of ECOG-ACRIN EA9213, I’m excited to see whether daratumumab can eradicate MRD in T-ALL, with the goal to improve depth of remission/ preventing relapse.”
Title: Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study
Authors: Teena Bhatla, Laura E. Hogan, David T. Teachey, Francisco Bautista, John Moppett, Pablo Velasco Puyó, Concetta Micalizzi, Claudia Rossig, Neerav Shukla, Gil Gilad, Franco Locatelli, André Baruchel, C. Michel Zwaan, Natalie S. Bezler, Alba Rubio-San-Simón, David C. Taussig, Elizabeth A. Raetz, Zhengwei J. Mao, Brent L. Wood, Diana Alvarez Arias, Maria Krevvata, Ivo Nnane, Nibedita Bandyopadhyay, Lorena Lopez Solano, Robyn M. Dennis, Robin Carson, Ajay Vora
Other articles featuring Talha Badar on OncoDaily.